On Nov. 17, 2021, Novavax announced that the European Medicines Agency (EMA) had begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax’ COVID-19 vaccine, marketed in the European Union under the brand name Nuvaxovidﾙ.